Eli Lilly bets $2.75B on AI drug discovery

Pharmaceutical giant Eli Lilly has entered into a significant $2.75 billion collaboration with Insilico Medicine, a Hong Kong-based company. This partnership aims to accelerate the discovery and development of new medications by leveraging Insilico's advanced artificial intelligence (AI) engine. The deal grants Eli Lilly exclusive rights to utilize the AI platform, signaling a major investment in AI-driven therapeutic innovation and a strategic move to bring AI-developed drugs to market.